| Vol. 4.27 – 24 July, 2020 |
| |
|
|
| Investigators performed single-cell RNA sequencing of whole human and mouse fetal livers throughout development. They identified four cell lineage families of endoderm-derived, erythroid, non-erythroid hematopoietic, and mesoderm-derived non-hematopoietic cells, and defined the developmental pathways of the major cell lineage families. [Cell Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that hepatic acyl-Coenzyme A oxidase 1, palmitoyl deficiency decreased the total cytosolic acetyl-CoA levels, which led to reduced acetylation of RPTOR/RAPTOR, a component of MTORC1, which is a key regulator of macroautophagy/autophagy. [Autophagy] |
|
|
|
| Using in vitro experiments, investigatora found that anlotinib had significant effects on proliferation inhibition, migration and invasion restraint, and cell-cycle arrestment in intrahepatic cholangiocarcinoma. [Cell Death & Disease] |
|
|
|
| The authors investigated insulin signaling, gluconeogenic gene expression, glucose production, and fatty acid synthase abundance in primary hepatocytes and in HepG2, Hepa 1–6, and McARH7777 hepatoma cell lines. [Scientific Reports] |
|
|
|
| Silencing Krüppel like factor 10 (Klf10) sensitized primary hepatocytes to apoptosis along with increased caspase 3 activation in response to TNFα. [Scientific Reports] |
|
|
|
| Researchers identified a network of positive and negative regulators of MYO18B mRNA expression which reflects the survival of hepatocellular carcinoma patients. [Scientific Reports] |
|
|
|
| Scientists investigated the combined effect of sorafenib and artesunate in inducing ferroptosis of hepatocellular carcinoma and elucidated the involved molecular mechanisms. [Acta Pharmacologica Sinica] |
|
|
|
| Researchers investigated the possible cytotoxic effects using normal BRL-3A and AML12 liver cells. [Human & Experimental Toxicology] |
|
|
|
|
| The authors focus on the clinical and pathophysiological connections between non-alcoholic fatty liver disease (NAFLD), insulin resistance and type 2 diabetes. [Diabetology & Metabolic Syndrome] |
|
|
|
|
| Terns Pharmaceuticals, Inc., has announced that it has dosed the first patient in the LIFT study, a Phase IIa clinical trial of TERN-101, a liver-selective farnesoid X receptor agonist, the company’s lead development candidate for the treatment of non-alcoholic steatohepatitis (NASH). [Terns Pharmaceuticals] |
|
|
|
| The French government this week unveiled a draft science bill that promises to increase public research spending with an extra €25 billion over the next ten years. [ScienceInsider] |
|
|
|
| Four Chinese nationals have been charged with visa fraud after revelations that they sent information on the layout of US labs and research carried out by colleagues back to China. [The Scientist] |
|
|
|
|
| September 10 – September 11 Virtual |
|
|
|
|
|
| Weill Cornell Medicine – New York, New York, United States |
|
|
|
| UT Health – San Antonio, Texas, United States |
|
|
|
| University of California – Davis, California, United States |
|
|
|
| Novo Nordisk A/S – Copenhagen, Denmark |
|
|
|
| Lund University Diabetes Centre – Lund, Sweden |
|
|
|
|